Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner


      The response to therapy with hypolipidemic agents shows considerable individual variation. These differences may be due to the interaction of environmental and genetic factors that affect drug bioavailability, receptor function or ligand structure. Our objective was to assess the effect of apolipoprotein (apo) E genotype and gender on lipid-lowering response to the HMG CoA reductase inhibitor, atorvastatin. Genotyping was carried out on DNA from 328 male and female subjects who participated in a multicentric, double-blind clinical trial, and received 10 mg/day of atorvastatin. Our data demonstrate no significant gender differences for LDL cholesterol levels at baseline. Moreover, mean LDL-C lowering was similar in men (−36.2%, range −2.7 to −57.8%) and in women (−38.1%, range −9.5 to −58.5%) as compared to baseline. However, men carrying the ε2 allele had a significantly higher mean LDL-C response (−44%) than ε3 homozygotes (−37%) and ε4 carriers (−34%); P=0.01 for apoE group by treatment interaction. No such gene/treatment interactions were noted in women, with those carrying the ε2 allele showing a similar mean response (−34%) as ε3 homozygotes (−39%) and ε4 carriers (−34%). Mean plasma triglyceride lowering with atorvastatin was 17%. A significant apoE group by treatment interaction (P=0.010) was also observed in men, with ε2 carriers being more responsive (−27%) than ε3/3 (−13%) and ε4 (−22%). This interaction was not observed in women. In summary, atorvastatin treatment had similar effects on plasma lipid levels in both men and women; however, the apoE gene locus was a significant predictor of LDL-C and TG responses to atorvastatin therapy in men, but not in women.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Expert Panel High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), J. Am. Med. Assoc. 1993; 269:3015–3023.

        • Kornitzer M.
        Primary and secondary prevention of coronary artery disease: a follow-up on clinical controlled trials.
        Curr. Opin. Lipidol. 1998; 9: 557-564
        • Cuchel M.
        • Schaefer E.J.
        • Millar J.S.
        • Jones P.J.
        • Dolnikowski G.G.
        • Vergani C.
        • Lichtenstein A.H.
        Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
        Arterioscl. Thromb. Vasc. Biol. 1997; 17: 1910-1917
        • Davidson M.
        • McKenney J.
        • Stein E.
        • Schrott H.G.
        • Fayyad R.
        • Black D.
        Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia.
        Am. J. Cardiol. 1997; 79: 1475-1481
        • Dart A.
        • Jerums G.
        • Nicholson G.
        • D'Emden M.
        • Hamilton-Craig I.
        • Tallis G.
        A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
        Am. J. Cardiol. 1997; 80: 39-44
        • Bertolini S.
        • Bittolo Bon G.
        • Campbell L.M.
        • Farnier M.
        • Langan J.
        • Mahla G.
        Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
        Atherosclerosis. 1997; 130: 191-197
        • Bakker-Arkema R.G.
        • Best J.
        • Fayyad R.
        • Heinonen T.M.
        • David Marais A.
        • Nawrocki J.W.
        • et al.
        A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.
        Atherosclerosis. 1997; 131: 17-23
        • Bakker-Arkema R.
        • Davidson M.
        • Goldstein R.
        • Davignon J.
        • Isaacsohn J.L.
        • Weiss S.R.
        Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
        J. Am. Med. Assoc. 1996; 275: 128-133
        • Best J.D.
        • Nicholson G.C.
        • O'Neal D.N.
        • Kotowicz M.A.
        • Tebbutt N.C.
        • Kin-Wah C.
        Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes.
        Diab. Nutr. Metab. 1996; 9: 74-80
        • Heinonen T.N.
        • Schrott H.G.
        • McKenney J.
        • Sniderman A.D.
        • Broyles F.E.
        • Zavoral J.H.
        Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol.
        J. Cardiovasc. Pharmacol. 1996; 2: 117-122
        • Ordovas J.M.
        • Schaefer E.J.
        Genes, variation of cholesterol and fat intake and serum lipids.
        Curr. Opin. Lipidol. 1999; 10: 15-22
        • Mahley R.W.
        Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.
        Science. 1988; 240: 622-630
        • Beisiegel U.
        • Weber W.
        • Ihrke G.
        • Herz J.
        • Stanley K.K.
        The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein.
        Nature. 1989; 341: 162-164
        • Allan C.M.
        • Walker D.
        • Segrest J.P.
        • Taylor J.M.
        Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus.
        Genomics. 1995; 28: 291-300
        • Davignon J.
        • Gregg R.E.
        • Sing C.F.
        Apolipoprotein E polymorphism and atherosclerosis.
        Arteriosclerosis. 1988; 8: 1-21
        • Rall S.C.
        • Weisgraber K.H.
        • Mahley R.W.
        Human apolipoprotein E: the complete amino acid sequence.
        J. Biol. Chem. 1982; 257: 4171-4178
        • Gregg R.E.
        • Zech L.A.
        • Schaefer E.J.
        • Brewer Jr., H.B.
        Apolipoprotein E metabolism in normolipoproteinemic human subjects.
        J. Lipid. Res. 1984; 25: 1167-1176
        • Schaefer E.J.
        • Lamon-Fava S.
        • Johnson S.
        • Ordovas J.M.
        • Schaefer M.M.
        • Castelli W.P.
        • et al.
        Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: results from the Framingham Offspring Study.
        Arterioscler. Thromb. 1994; 14: 1105-1113
        • Nestruck A.C.
        • Bouthillier D.
        • Sing C.F.
        • Davignon J.
        Apolipoprotein E polymorphism and plasma cholesterol response to probucol.
        Metabolism. 1987; 36: 743-747
        • Eto M.
        • Sato T.
        • Watanabe K.
        • Iwashima Y.
        • Makino I.
        Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with or without apolipoprotein E4.
        Atherosclerosis. 1990; 84: 49-53
        • Nemeth A.
        • Szakmary K.A.
        • Kramer J.
        • Dinya E.
        • Pados G.
        • Fust G.
        • et al.
        Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy.
        Eur. J. Clin. Chem. Clin. Biochem. 1995; 33: 799-804
        • Yamada M.
        Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients.
        J. Atheroscler. Thromb. 1997; 4: 40-44
        • Carmena R.
        • Roederer G.
        • Mailloux H.
        • Lussier-Cacan S.
        • Davignon J.
        The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
        Metabolism. 1993; 42: 895-901
        • Ojala J.-P.
        • Helve E.
        • Ehnholm C.
        • Aalto-Setala K.
        • Kontula K.K.
        • Tikkanen M.J.
        Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.
        J. Intern. Med. 1991; 230: 397-405
        • O'Malley J.P.
        • Illingworth D.R.
        The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia.
        Metabolism. 1990; 39: 150-154
        • de Knijff P.
        • Stalenhoef A.F.H.
        • Mol M.J.T.M.
        • Gevers Leuven J.A.
        • Smit J.
        • Erkelens D.W.
        • et al.
        Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
        Atherosclerosis. 1990; 83: 89-97
        • Ordovas J.M.
        • Lopez-Miranda J.
        • Perez-Jimenez F.
        • Rodriguez C.
        • Park J.-S.
        • Cole T.
        • et al.
        Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
        Atherosclerosis. 1995; 113: 157-166
        • Miller S.A.
        • Dykes D.D.
        • Polesky H.F.
        A simple salting out procedure for extracting DNA from human nucleated cells.
        Nucleic. Acids Res. 1989; 16: 1215
        • Hixson J.E.
        • Vernier D.T.
        Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
        J. Lipid. Res. 1990; 31: 545-548
        • Nestel P.
        • Simons L.
        • Barter P.
        • Clifton P.
        • Colquhoun D.
        • Hamilton-Craig I.
        • et al.
        A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apoE genotype, lipoprotein(a) and insulin.
        Atherosclerosis. 1997; 129: 231-239
        • Sanllehy C.
        • Casals E.
        • Rodriguez-Villar C.
        • Zambon D.
        • Ojuel J.
        • Ballesta A.M.
        • et al.
        Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia.
        Metabol.: Clin. Exp. 1998; 47: 560-565
        • Wierzbicki A.
        • Lumb P.J.
        • Chick G.
        • Crook M.A.
        High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
        Am. J. Cardiol. 2000; 86: 547-549
        • Stein E.A.
        • Lane M.
        • Larkarzewski P.
        Comparison of statins in hypertriglyceridemic.
        Am. J. Cardiol. 1998; 81: 66B-69B
        • Ordovas J.M.
        The genetics of serum lipid responsiveness to dietary interventions.
        Proc. Nutr. Soc. 1999; 58: 171-187
        • Miettinen T.A.
        • Gylling H.
        • Strandberg T.
        • Sarna S.
        Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators.
        Br. Med. J. 1998; 316: 1127-1130
        • Gylling H.
        • Miettinen T.A.
        Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes.
        J. Lipid Res. 1992; 33: 1361-1371
        • Kesaniemi Y.A.
        • Ehnholm C.
        • Miettinen T.A.
        Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype.
        J. Clin. Invest. 1987; 80: 578-581